Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

Clinical trial NCT05084638 · COMPLETED

Trial details

NCT number: NCT05084638
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Relapse Remitting Multiple Sclerosis

Start date: 2022-01-25
Primary completion: 2025-02-04
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.